National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

Journal of the American Academy of Dermatology

Volumn 58, Issue 6, 2008, Pages 1031-1042

  Kimball, Alexa B ^a   Gladman, Dafna ^d   Gelfand, Joel M ^e   Gordon, Kenneth ^f   Horn, Elizabeth J ^g   Korman, Neil J ^h   Korver, Gretchen ^b   Krueger, Gerald G ^b   Strober, Bruce E ⁱ   Lebwohl, Mark G ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Division of Dermatology   (United States)

^g National Psoriasis Foundation   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COAL TAR; CYCLOSPORIN; METHOTREXATE; PSORALEN;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; CANCER RISK; CARDIOVASCULAR RISK; COMORBIDITY; CONSENSUS; DEPRESSION; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; METABOLIC SYNDROME X; OBESITY; PATIENT COUNSELING; PATIENT REFERRAL; PHOTOTHERAPY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SCREENING TEST; SKIN INFECTION; SMOKING HABIT; ULTRAVIOLET A RADIATION;

CARDIOVASCULAR DISEASES; HUMANS; INFECTION; NEOPLASMS; PSORIASIS; RISK FACTORS;

EID: 43449137849     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.01.006     Document Type: Review

References (143)

1. Feldman S.R., Ravis S., Moran W.P., and Fleischer Jr. A.B. Patients seen in a dermatology clinic have unmet preventive health care needs. J Am Acad Dermatol 44 (2001) 706-709
2. Gelfand J.M., Troxel A.B., Lewis J.D., Kurd S.K., Shin D.B., Wang X., et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol 143 (2007) 1493-1499
3. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., et al. Psoriasis: A possible risk factor for development of coronary artery calcification. Br J Dermatol 156 (2007) 271-276
4. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
5. McDonald C.J., and Calabresi P. Complication of psoriasis. JAMA 224 (1973) 629
6. Mallbris L., Akre O., Granath F., Yin L., Lindelöf B., Ekbom A., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
7. Fortes C., Mastroeni S., Leffondré K., Sampogna F., Melchi F., Mazzotti E., et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141 (2005) 1580-1584
8. Gupta M.A., Gupta A.K., and Watteel G.N. Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. Br J Dermatol 135 (1996) 859-860
9. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
10. Naldi L., Parazzini F., Brevi A., Peserico A., Veller Fornasa C., Grosso G., et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 127 (1992) 212-217
11. Naldi L., Peli L., and Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: Evidence from an Italian case-control study. Arch Dermatol 135 (1999) 1479-1484
12. Zhang X., Wang H., Te-Shao H., Yang S., and Wang F. Frequent use of tobacco and alcohol in Chinese psoriasis patients. Int J Dermatol 41 (2002) 659-662
13. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., and Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
14. Stern R.S., and Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 91 (1988) 197-201
15. Prodanovich S., Ma F., Taylor J.R., Pezon C., Fasihi T., and Kirsner R.S. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52 (2005) 262-267
16. Binazzi M., Calandra P., and Lisi P. Statistical association between psoriasis and diabetes: Further results. Arch Dermatol Res 254 (1975) 43-48
17. Brenelli S.L., Moraes A.M., Monte-Alegre S., Carvalho O.M., and Saad M.J. Insulin resistance in psoriasis. Braz J Med Biol Res 28 (1995) 297-301
18. Fratino P., Pelfini C., Jucci A., and Bellazzi R. Glucose and insulin in psoriasis: The role of obesity and diabetic genetic history. Panminerva Med 21 (1979) 167-172
19. Pelfini C., Jucci A., Fratino P., De Marco R., and Serri F. Insulinogenic indexes in psoriasis. Acta Derm Venereol Suppl (Stockh) 87 (1979) 48-50
20. Mallbris L., Granath F., Hamsten A., and Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54 (2006) 614-621
21. Piskin S., Gurkok F., Ekuklu G., and Senol M. Serum lipid levels in psoriasis. Yonsei Med J 44 (2003) 24-26
22. Ucak S., Ekmekci T.R., Basat O., Koslu A., and Altuntas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 20 (2006) 517-522
23. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
24. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
25. Sterry W., Strober B.E., and Menter A. Obesity in psoriasis: The metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 157 (2007) 649-655
26. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
27. Skilton M.R., Moulin P., Serusclat A., Nony P., and Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: Evidence for sex-specific differences. Atherosclerosis 190 (2007) 416-422
28. American Heart Association Web site. Metabolic syndrome. Available at: http://www.americanheart.org/presenter.jhtml?identifier=4756. Accessed December 20, 2007.
29. Cigarette smoking among adults-United States, 2004. MMWR Morb Mortal Wkly Rep 54 (2005) 1121-1124
30. Petersen S., and Peto V. Smoking statistics (2004), British Heart Foundation, London
31. McGinnis J.M., and Hamburg M.A. Opportunities for health promotion and disease prevention in the clinical setting. West J Med 149 (1988) 468-474
32. Poikolainen K., Reunala T., and Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 130 (1994) 473-477
33. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
34. Mills C.M., Srivastava E.D., Harvey I.M., Swift G.L., Newcombe R.G., Holt P.J., et al. Smoking habits in psoriasis: A case control study. Br J Dermatol 127 (1992) 18-21
35. Braathen L.R., Botten G., and Bjerkedal T. Psoriatics in Norway. A questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm Venereol Suppl (Stockh) 142 (1989) 9-12
36. Setty A.R., Curhan G., and Choi H.K. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 120 (2007) 953-959
37. Wyatt S.B., Winters K.P., and Dubbert P.M. Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 331 (2006) 166-174
38. Prentice A.M. The emerging epidemic of obesity in developing countries. Int J Epidemiol 35 (2006) 93-99
39. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., and Ellis C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
40. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 356 (2000) 385-390
41. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
42. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
43. McGowan J.W., Pearce D.J., Chen J., Richmond D., Balkrishnan R., and Feldman S.R. The skinny on psoriasis and obesity. Arch Dermatol 141 (2005) 1601-1602
44. Setty A.R., Curhan G., and Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 (2007) 1670-1675
45. de Menezes Ettinger J.E., Azaro E., de Souza C.A., dos Santos Filho P.V., Mello C.A., Neves Jr. M., et al. Remission of psoriasis after open gastric bypass. Obes Surg 16 (2006) 94-97
46. Higa-Sansone G., Szomstein S., Soto F., Brasecsco O., Cohen C., and Rosenthal R.J. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 14 (2004) 1132-1134
47. Frasure-Smith N., and Lesperance F. Recent evidence linking coronary heart disease and depression. Can J Psychiatry 51 (2006) 730-737
48. Wulsin L.R. Is depression a major risk factor for coronary disease? A systematic review of the epidemiologic evidence. Harv Rev Psychiatry 12 (2004) 79-93
49. Mease P.J., and Menter M.A. Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 54 (2006) 685-704
50. Esposito M., Saraceno R., Giunta A., Maccarone M., and Chimenti S. An Italian study on psoriasis and depression. Dermatology 212 (2006) 123-127
51. Gupta M.A., and Gupta A.K. Psoriasis and sex: A study of moderately to severely affected patients. Int J Dermatol 36 (1997) 259-262
52. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35
53. Glassman A.H., and Bigger Jr. J.T. Antidepressants in coronary heart disease: SSRIs reduce depression, but do they save lives?. JAMA 297 (2007) 411-412
54. Screening for depression: Recommendations and rationale (2002), Agency for Healthcare Research and Quality: US Preventative Services Task Force, Rockville (MD)
55. Soderlin M.K., Lindroth Y., and Jacobsson L.T. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmö, Sweden. Rheumatology (Oxford) 46 (2007) 1355-1358
56. Poikolainen K., Reunala T., Karvonen J., Lauharanta J., and Karkkainen P. Alcohol intake: A risk factor for psoriasis in young and middle aged men?. BMJ 300 (1990) 780-783
57. Higgins E.M., Peters T.J., and du Vivier A.W. Smoking, drinking and psoriasis. Br J Dermatol 129 (1993) 749-750
58. Gupta M.A., Schork N.J., Gupta A.K., and Ellis C.N. Alcohol intake and treatment responsiveness of psoriasis: A prospective study. J Am Acad Dermatol 28 5 pt 1 (1993) 730-732
59. Poikolainen K., Karvonen J., and Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 135 (1999) 1490-1493
60. Delaney T.J., and Leppard B. Alcohol intake and psoriasis. Acta Derm Venereol 54 (1974) 237-238
61. Chaput J.C., Poynard T., Naveau S., Penso D., Durrmeyer O., and Suplisson D. Psoriasis, alcohol, and liver disease. Br Med J (Clin Res Ed) 291 (1985) 25
62. Sommer D.M., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
63. Green M.S., Prystowsky J.H., Cohen S.R., Cohen J.I., and Lebwohl M.G. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 34 5 pt 2 (1996) 911-914
64. Condon C., and Lyons J.F. Extensive unstable psoriasis-Morbidity and medical management. Ir J Med Sci 163 (1994) 381-383
65. Christophers E., and Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res 279 suppl (1987) S48-S51
66. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171 (2003) 3262-3269
67. Lambert J.R., and Wright V. Surgery in patients with psoriasis and arthritis. Rheumatol Rehabil 18 (1979) 35-37
68. Beyer C.A., Hanssen A.D., Lewallen D.G., and Pittelkow M.R. Primary total knee arthroplasty in patients with psoriasis. J Bone Joint Surg Br 73 (1991) 258-259
69. Hicken G.J., Kitaoka H.B., and Valente R.M. Foot and ankle surgery in patients with psoriasis. Clin Orthop Relat Res 300 (1994) 201-206
70. Menon T.J., and Wroblewski B.M. Charnley low-friction arthroplasty in patients with psoriasis. Clin Orthop Relat Res 176 (1983) 127-128
71. Stern S.H., Insall J.N., Windsor R.E., Inglis A.E., and Dines D.M. Total knee arthroplasty in patients with psoriasis. Clin Orthop Relat Res 248 (1989) 108-110
72. Drancourt M., Argenson J.N., Tissot Dupont H., Aubaniac J.M., and Raoult D. Psoriasis is a risk factor for hip-prosthesis infection. Eur J Epidemiol 13 (1997) 205-207
73. Saini R., and Shupack J.L. Psoriasis: To cut or not to cut, what say you?. Dermatol Surg 29 (2003) 735-740
74. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103 (1999) 1243-1252
75. Gottlieb A.B., Casale T.B., Frankel E., Goffe B., Lowe N., Ochs H.D., et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 49 (2003) 816-825
76. Lebwohl M., Bagel J., Gelfand J.M., Gladman D., Gordon K.B., Hsu S., et al. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58 (2008) 94-105
77. Krueger J.G., and Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 64 suppl 2 (2005) ii30-ii36
78. Margolis D., Bilker W., Hennessy S., Vittorio C., Santanna J., and Strom B.L. The risk of malignancy associated with psoriasis. Arch Dermatol 137 (2001) 778-783
79. Frentz G., and Olsen J.H. Malignant tumours and psoriasis: A follow-up study. Br J Dermatol 140 (1999) 237-242
80. Boffetta P., Gridley G., and Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 117 (2001) 1531-1537
81. Zhang Y., Holford T.R., Leaderer B., Zahm S.H., Boyle P., Morton L.M., et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15 (2004) 419-428
82. Gelfand J.M., Berlin J., Van Voorhees A., and Margolis D.J. Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom. Arch Dermatol 139 (2003) 1425-1429
83. Hannuksela-Svahn A., Pukkala E., Laara E., Poikolainen K., and Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 114 (2000) 587-590
84. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E., Lindelöf B., Berne B., Hannuksela M., et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 141 (1999) 497-501
85. Morales M.M., Olsen J., Johansen P., Kaerlev L., Guénel P., Arveux P., et al. Viral infection, atopy and mycosis fungoides: A European multicentre case-control study. Eur J Cancer 39 (2003) 511-516
86. Soderberg K.C., Jonsson F., Winqvist O., Hagmar L., and Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: A nationwide case-control study in Sweden. Eur J Cancer 42 (2006) 3028-3033
87. Hannuksela A., Pukkala E., Hannuksela M., and Karvonen J. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. J Am Acad Dermatol 35 5 pt 1 (1996) 685-689
88. Lindelof B., and Eklund G. Incidence of malignant skin tumors in 14,140 patients after grenz-ray treatment for benign skin disorders. Arch Dermatol 122 (1986) 1391-1395
89. Doody M.M., Linet M.S., Glass A.G., Friedman G.D., Pottern L.M., Boice Jr. J.D., et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 3 (1992) 449-456
90. Frentz G., Olsen J.H., and Avrach W.W. Malignant tumours and psoriasis: Climatotherapy at the Dead Sea. Br J Dermatol 141 (1999) 1088-1091
91. Olsen J.H., Moller H., and Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 27 5 pt 1 (1992) 716-722
92. Stern R.S. Lymphoma risk in psoriasis: Results of the PUVA follow-up study. Arch Dermatol 142 (2006) 1132-1135
93. Stern R.S., Fitzgerald E., Ellis C.N., Lowe N., Goldfarb M.T., and Baughman R.D. The safety of etretinate as long-term therapy for psoriasis: Results of the etretinate follow-up study. J Am Acad Dermatol 33 (1995) 44-52
94. Stern R.S., and Vakeva L.H. Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol 108 (1997) 897-900
95. Becker N., Deeg E., Rudiger T., and Nieters A. Medical history and risk for lymphoma: Results of a population-based case-control study in Germany. Eur J Cancer 41 (2005) 133-142
96. Smedby K.E., Hjalgrim H., Askling J., Chang E.T., Gregersen H., Porwit-MacDonald A., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98 (2006) 51-60
97. Tavani A., La Vecchia C., Franceschi S., Serraino D., and Carbone A. Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev 9 (2000) 59-64
98. Gelfand J.M., Shin D.B., Neimann A.L., Wang X., Margolis D.J., and Troxel A.B. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 (2006) 2194-2201
99. Kamel O.W., Weiss L.M., van de Rijn M., Colby T.V., Kingma D.W., and Jaffe E.S. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 20 (1996) 1279-1287
100. Kamel O.W. Lymphomas during long-term methotrexate therapy. Arch Dermatol 133 (1997) 903-904
101. Paul C.F., Ho V.C., McGeown C., Christophers E., Schmidtmann B., Guillaume J.C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
102. Alderson M.R., and Clarke J.A. Cancer incidence in patients with psoriasis. Br J Cancer 47 (1983) 857-859
103. Lindelöf B., Sigurgeirsson B., Tegner E., Larkö O., Johannesson A., Berne B., et al. PUVA and cancer: A large-scale epidemiological study. Lancet 338 (1991) 91-93
104. Lindelöf B., Sigurgeirsson B., Tegner E., Larkö O., Johannesson A., Berne B., et al. PUVA and cancer risk: The Swedish follow-up study. Br J Dermatol 141 (1999) 108-112
105. Stern R.S., and Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 134 (1998) 1582-1585
106. Lindelof B., and Sigurgeirsson B. PUVA and cancer: A case-control study. Br J Dermatol 129 (1993) 39-41
107. Arellano F. Risk of cancer with cyclosporine in psoriasis. Int J Dermatol 36 suppl 1 (1997) 15-17
108. Gupta A.K., Stern R.S., Swanson N.A., and Anderson T.F. Cutaneous melanomas in patients treated with psoralens plus ultraviolet A. A case report and the experience of The PUVA Follow-Up Study. J Am Acad Dermatol 19 1 pt 1 (1988) 67-76
109. Stern R.S., Nichols K.T., and Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 336 (1997) 1041-1045
110. Smith R.A., Cokkinides V., and Eyre H.J. Cancer screening in the United States, 2007: A review of current guidelines, practices, and prospects. CA Cancer J Clin 57 (2007) 90-104
111. Gladman D.D. Epidemiology. Psoriatic arthritis. In: Gordon K.B., and Ruderman E. (Eds). Psoriasis and psoriatic arthritis: An integrated approach (2005), Springer-Verlag, Heidelberg 57-65
112. Gelfand J.M., Gladman D.D., Mease P.J., Smith N., Margolis D.J., Nijsten T., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53 (2005) 573
113. Gladman D.D., Anhorn K.A., Schachter R.K., and Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 13 (1986) 586-592
114. Wong K., Gladman D.D., Husted J., Long J.A., and Farewell V.T. Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40 (1997) 1868-1872
115. Ali Y., Tom B.D., Schentag C.T., Farewell V.T., and Gladman D.D. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 56 (2007) 2708-2714
116. Gladman D.D., Farewell V.T., Wong K., and Husted J. Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41 (1998) 1103-1110
117. Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A., and Nurmohamed M.T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34 (2004) 585-592
118. Kimhi O., Caspi D., Bornstein N.M., Maharshak N., Gur A., Arbel Y., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36 (2007) 203-209
119. Han C., Robinson Jr. D.W., Hackett M.V., Paramore L.C., Fraeman K.H., and Bala M.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33 (2006) 2167-2172
120. Bruce I.N., Schentag C.T., and Gladman D.D. Hyperuricemia in psoriatic arthritis: Prevalence and associated features. J Clin Rheumatol 6 (2000) 6-9
121. Gonzalez-Juanatey C., Amigo-Diaz E., Miranda-Filloy J.A., Testa A., Revuelta J., Garcia-Porrua C., et al. Lack of echocardiographic and Doppler abnormalities in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Semin Arthritis Rheum 35 (2006) 333-339
122. Rohekar S., Hassa A., Schentag C., and Gladman D. Malignancy in psoriaic arthritis (PsA). J Rheumatol 33 (2006) 392
123. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
124. Gladman D.D., Mease P.J., Ritchlin C.T., Choy E.H., Sharp J.T., Ory P.A., et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56 (2007) 476-488
125. Kavanaugh A., Antoni C.E., Gladman D., Wassenberg S., Zhou B., Beutler A., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. Ann Rheum Dis 65 (2006) 1038-1043
126. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., and Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 54 (2006) 2665-2673
127. Robinson Jr. D., Hackett M., Wong J., Kimball A.B., Cohen R., and Bala M. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: An exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 22 (2006) 989-1000
128. Najarian D.J., and Gottlieb A.B. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 48 (2003) 805-821
129. Broadley S.A., Deans J., Sawcer S.J., Clayton D., and Compston D.A. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 123 pt 6 (2000) 1102-1111
130. Alemany-Rodríguez M.J., Aladro Y., Amela-Peris R., Pérez-Viéitez M.C., Reyes-Yáñez M.P., Déniz-Naranjo M.C., et al. Autoimmune diseases and multiple sclerosis. [in Spanish]. Rev Neurol 40 (2005) 594-597
131. Moll J.M., Haslock I., Macrae I.F., and Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behçet's syndrome. Medicine (Baltimore) 53 (1974) 343-364
132. Yates V.M., Watkinson G., and Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 106 (1982) 323-330
133. Hughes S., Williams S.E., and Turnberg L.A. Crohn's disease and psoriasis. N Engl J Med 308 (1983) 101
134. Lee F.I., Bellary S.V., and Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 85 (1990) 962-963
135. Hugot J.P., Laurent-Puig P., Gower-Rousseau C., Olson J.M., Lee J.C., Beaugerie L., et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379 (1996) 821-823
136. Hampe J., Schreiber S., Shaw S.H., Lau K.F., Bridger S., Macpherson A.J., et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 64 (1999) 808-816
137. Nair R.P., Stuart P., Henseler T., Jenisch S., Chia N.V., Westphal E., et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66 (2000) 1833-1844
138. Nair R.P., Henseler T., Jenisch S., Stuart P., Bichakjian C.K., Lenk W., et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 6 (1997) 1349-1356
139. Nickoloff B.J., Karabin G.D., Barker J.N., Griffiths C.E., Sarma V., Mitra R.S., et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138 (1991) 129-140
140. Wakefield P.E., James W.D., Samlaska C.P., and Meltzer M.S. Tumor necrosis factor. J Am Acad Dermatol 24 5 pt 1 (1991) 675-685
141. Braegger C.P., Nicholls S., Murch S.H., Stephens S., and MacDonald T.T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339 (1992) 89-91
142. Murch S.H., Braegger C.P., Walker-Smith J.A., and MacDonald T.T. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34 (1993) 1705-1709
143. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80 (2007) 273-290